Commercialization
-
Sponsored by Phil Inc
Optimizing your hub services program with a gross-to-net lens
In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.
Sept. 25, 2023 -
Q&A
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Q&A
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
By Michael Gibney • Aug. 30, 2023 -
Are weight loss drugs a win for the global economy?
As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market.
By Karissa Waddick • Aug. 28, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023 -
Demand for weight loss drugs soars to nearly half of Americans
Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.
By Alexandra Pecci • Aug. 15, 2023 -
Podcast
Woman of the Week: Novartis’ Christy Siegel
The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.
By Taren Grom and Meagan Parrish • Aug. 15, 2023 -
PBMs could soon feel the regulatory sting
From Congress to the FTC to state legislatures, regulators are cracking the whip against PBMs.
By Karissa Waddick • Aug. 4, 2023 -
Profile
Putting purpose over profits, this pharma takes on the important issues
Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.
By Alexandra Pecci • Aug. 1, 2023 -
Threads joins the social media fray. Here’s what it means for pharma marketers.
Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.
By Karissa Waddick • July 18, 2023 -
Q&A // First 90 Days
A BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.
By Karissa Waddick • July 5, 2023 -
Podcast
Woman of the Week: Gamida Cell’s Abbey Jenkins
The first-time CEO discusses the lessons she has learned since taking the role last year and how she’s pivoting the company into a commercial entity.
By Taren Grom • June 14, 2023 -
Q&A
Ranking reveals biopharma’s most innovative companies
IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.
By Taren Grom • June 7, 2023 -
Podcast
Woman of the Week: Marinus Pharmaceuticals’ Christy Shafer
The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.
By Taren Grom • June 7, 2023 -
Opinion
A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking
Healthcare pros share the market drivers they believe are having the biggest impact on the industry.
By Taren Grom • June 2, 2023 -
Podcast
Woman of the Week: Mirati Therapeutics’ Laurie Stelzer
With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.
By Taren Grom • May 31, 2023 -
Taking your biotech global? Here’s how you can navigate cultural norms
What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.
By Alexandra Pecci • May 2, 2023 -
Q&A
5 minutes with — Parexel’s Peyton Howell
The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."
By Taren Grom • April 7, 2023 -
A drug just launched for a disease discovered only 10 years ago
Pharming just landed an FDA approval for a treatment targeting an ultra-rare immunodeficiency disorder discovered only a decade ago — and it’s already in the hands of patients.
By Karissa Waddick • April 6, 2023 -
Cutting the cord — why streaming is a new frontier for pharma advertising
As streaming services proliferate, and more TV watchers buy in, there’s a new world of possibilities for DTC pharma marketing.
By Karissa Waddick • March 27, 2023 -
Podcast
Woman of the Week: Novartis Gene Therapies’ Chris Fox
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...
By Taren Grom • March 15, 2023